AllovirInc Stock Analysis

ALVR
 Stock
  

USD 7.01  0.50  6.66%   

The modest gains experienced by current holders of AllovirInc could raise concerns from retail investors as the firm is trading at a share price of 7.01 on 179,035 in volume. The company management teams have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.4. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the AllovirInc partners.
Please continue to Trending Equities.
  
The AllovirInc stock analysis report makes it easy to digest most publicly released information about AllovirInc and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. AllovirInc Stock analysis module also helps to analyze the AllovirInc price relationship with some important fundamental indicators such as market cap and management efficiency.

AllovirInc Stock Analysis Notes

About 50.0% of the company shares are held by company insiders. The book value of AllovirInc was presently reported as 2.82. The company recorded a loss per share of 2.92. AllovirInc had not issued any dividends in recent years. The entity had 1:10 split on the April 2, 2013. Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people. For more info on AllovirInc please contact Assaf Katan at 617 433 2605 or go to https://www.allovir.com.

AllovirInc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. AllovirInc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding AllovirInc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
AllovirInc has very high historical volatility over the last 90 days
Net Loss for the year was (171.96 M) with profit before overhead, payroll, taxes, and interest of 165 K.
AllovirInc currently holds about 172.67 M in cash with (106.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Roughly 50.0% of the company shares are held by company insiders

AllovirInc Upcoming and Recent Events

Earnings reports are used by AllovirInc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AllovirInc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

AllovirInc Largest EPS Surprises

Earnings surprises can significantly impact AllovirInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-02-11
2020-12-31-0.42-0.340.0819 
2021-05-06
2021-03-31-0.4-0.5-0.125 
2022-05-05
2022-03-31-0.8-0.690.1113 
View All Earnings Estimates

AllovirInc SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. AllovirInc prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that AllovirInc investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial AllovirInc specific information freely available to individual and institutional investors to make a timely investment decision.
5th of August 2022
Unclassified Corporate Event. Unclassified Corporate Event
View
4th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
27th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
19th of May 2022
Submission of Matters to a Vote of Security Holders
View
5th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
31st of March 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
10th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
9th of February 2022
Unclassified Corporate Event
View

AllovirInc Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 667.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AllovirInc's market, we take the total number of its shares issued and multiply it by AllovirInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (0.3822) % which means that it has lost $0.3822 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.7243) %, meaning that it created substantial loss on money invested by shareholders. AllovirInc management efficiency ratios could be used to measure how well allovirinc manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of December, AllovirInc shows the Downside Deviation of 5.29, mean deviation of 4.41, and Risk Adjusted Performance of 0.0598. AllovirInc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for AllovirInc, which can be compared to its rivals. Please confirm AllovirInc downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if AllovirInc is priced correctly, providing market reflects its regular price of 7.01 per share. Given that AllovirInc has jensen alpha of 0.0962, we suggest you to validate AllovirInc's prevailing market performance to make sure the company can sustain itself at a future point.

AllovirInc Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as AllovirInc price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

AllovirInc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AllovirInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on AllovirInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AllovirInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

AllovirInc Technical and Predictive Indicators

AllovirInc Forecast Models

AllovirInc time-series forecasting models is one of many AllovirInc's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AllovirInc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About AllovirInc Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how AllovirInc prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AllovirInc shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as AllovirInc. By using and applying AllovirInc Stock analysis, traders can create a robust methodology for identifying AllovirInc entry and exit points for their positions.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.

Current AllovirInc Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AllovirInc analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AllovirInc analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
42.75Buy4Odds
AllovirInc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most AllovirInc analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AllovirInc stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AllovirInc, talking to its executives and customers, or listening to AllovirInc conference calls.
AllovirInc Analyst Advice Details

AllovirInc Stock Analysis Indicators

AllovirInc stock analysis indicators help investors evaluate how AllovirInc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AllovirInc shares will generate the highest return on investment. By understating and applying AllovirInc stock analysis, traders can identify AllovirInc position entry and exit signals to maximize returns.
Begin Period Cash Flow122661000.00
Logo U R LimglogosUSALVR.png
Common Stock Shares Outstanding26897390.00
Total Stockholder Equity225266000.00
DescriptionAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. The companys lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to tre
Total Cashflows From Investing Activities185983000.00
Tax Provision1007000.00
Property Plant And Equipment Net31292000.00
Retained Earnings-297065000.00
Cash And Short Term Investments47311000.00
Retained Earnings Total Equity-297065000.00
Cash852000.00
CodeALVR
Accounts Payable8361000.00
Net Debt35805000.00
50 Day M A7.9164
Total Current Liabilities37853000.00
Currency CodeUSD
Non Current Assets Total33246000.00
Common Stock Total Equity7000.00
Non Currrent Assets Other1954000.00
Please continue to Trending Equities. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running AllovirInc price analysis, check to measure AllovirInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AllovirInc is operating at the current time. Most of AllovirInc's value examination focuses on studying past and present price action to predict the probability of AllovirInc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AllovirInc's price. Additionally, you may evaluate how the addition of AllovirInc to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Is AllovirInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AllovirInc. If investors know AllovirInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AllovirInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
668 M
Return On Assets
(0.38) 
Return On Equity
(0.72) 
The market value of AllovirInc is measured differently than its book value, which is the value of AllovirInc that is recorded on the company's balance sheet. Investors also form their own opinion of AllovirInc's value that differs from its market value or its book value, called intrinsic value, which is AllovirInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AllovirInc's market value can be influenced by many factors that don't directly affect AllovirInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AllovirInc's value and its price as these two are different measures arrived at by different means. Investors typically determine AllovirInc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AllovirInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.